Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPE-A Followed by XPE-A in Head and Neck Cancer
NCT01262859Phase 2Withdrawn
- Sponsor
- University of Pittsburgh
- Start
- Dec 2010
- Primary completion
- Jul 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in squamous cell carcinoma of the head and neck (HNSCC), sponsored by University of Pittsburgh. Planned start Dec 2010; status: withdrawn.
02
Drugs
bevacizumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT01262859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01262859.